151

Ocrelizumab 300mg Concentrate for Solution for Infusion

Prescriber Criteria: Consultant Neurologist

Inpatient use:

1. Multiple Sclerosis

Treatment of adult patients with any one of the following:

- Early primary progressive multiple sclerosis.
- Active multiple sclerosis with a suboptimal treatment response following six months treatment with first-line interferon beta-1a, interferon beta-1b, teriflunomide, or dimethyl fumarate.
- Relapsing-remitting multiple sclerosis with the presence of poor prognostic indicators.
- Rapidly evolving severe multiple sclerosis.

An official approval from the Medicines Approval Section (permit) is required.

Duration of Approval:
1 year